

**APPLICANT** (stamp or sticker acceptable)      **PATIENT NHI:** .....      **REFERRER** Reg No: .....

Reg No: .....      First Names: .....      First Names: .....

Name: .....      Surname: .....      Surname: .....

Address: .....      DOB: .....      Address: .....

.....      Address: .....      .....

.....      .....

Fax Number: .....      Fax Number: .....

**Benralizumab**

**Initial application — Severe eosinophilic asthma**

Applications only from a respiratory physician or clinical immunologist. Approvals valid for 12 months.

**Prerequisites**(tick boxes where appropriate)

- Patient must be aged 12 years or older
- and  Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist
- and  Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded
- and  Patient has a blood eosinophil count of greater than  $0.5 \times 10^9$  cells/L in the last 12 months
- and  Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated
- and  Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids
- or  Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months
- and  Treatment is not to be used in combination with subsidised mepolizumab
- and  Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment
- and  Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma
- or  Patient was refractory or intolerant to previous anti-IL5 biological therapy
- and  Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment

**Renewal — Severe eosinophilic asthma**

Current approval Number (if known):.....

Applications only from a respiratory physician or clinical immunologist. Approvals valid for 2 years.

**Prerequisites**(tick boxes where appropriate)

- An increase in the Asthma Control Test (ACT) score of at least 5 from baseline
- and  Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab
- or  Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)